IL312903A - Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59 - Google Patents

Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59

Info

Publication number
IL312903A
IL312903A IL312903A IL31290324A IL312903A IL 312903 A IL312903 A IL 312903A IL 312903 A IL312903 A IL 312903A IL 31290324 A IL31290324 A IL 31290324A IL 312903 A IL312903 A IL 312903A
Authority
IL
Israel
Prior art keywords
amd
drp
gene therapy
vector expressing
therapy vector
Prior art date
Application number
IL312903A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL312903A publication Critical patent/IL312903A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL312903A 2021-11-19 2022-11-18 Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59 IL312903A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163281190P 2021-11-19 2021-11-19
PCT/IB2022/061158 WO2023089564A1 (en) 2021-11-19 2022-11-18 Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59

Publications (1)

Publication Number Publication Date
IL312903A true IL312903A (en) 2024-07-01

Family

ID=84365536

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312903A IL312903A (en) 2021-11-19 2022-11-18 Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59

Country Status (11)

Country Link
US (1) US20250018063A1 (https=)
EP (1) EP4433496A1 (https=)
JP (1) JP2024540470A (https=)
KR (1) KR20240107156A (https=)
CN (1) CN118369333A (https=)
AU (1) AU2022394125A1 (https=)
CA (1) CA3237907A1 (https=)
IL (1) IL312903A (https=)
JO (1) JOP20240112A1 (https=)
MX (1) MX2024006087A (https=)
WO (1) WO2023089564A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025074268A1 (en) * 2023-10-02 2025-04-10 Janssen Biotech, Inc. Methods for treating macular degeneration
WO2025083169A1 (en) * 2023-10-17 2025-04-24 Tenpoint Therapeutics Limited Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
AU4404785A (en) 1984-05-25 1985-12-31 Dana-Farber Cancer Institute, Inc. Ltr vectors, methods of preparation and use
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
US5112767A (en) 1988-03-04 1992-05-12 University Of Southern California Vectors with enhancer domains
US6677311B1 (en) 1988-07-20 2004-01-13 The Salk Institute For Biological Studies Inducible HSV-TK in transformed cell populations
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
WO1990002797A1 (en) 1988-09-15 1990-03-22 North Carolina State University Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
WO1990013641A1 (en) 1989-05-10 1990-11-15 Sloan-Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
US5122767A (en) 1991-01-10 1992-06-16 Northern Telecom Limited Saw device tapped delay lines
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2002068627A2 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constucts
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
AU2008295509A1 (en) 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
JP5697027B2 (ja) 2008-02-15 2015-04-08 タフツ ユニバーシティー マウス網膜上への細胞膜傷害複合体（ｍａｃ）生成のヒト化モデル、並びに、黄斑変性の処置のための組成物とキットと方法
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
ES2992014T3 (es) * 2018-02-12 2024-12-05 Tufts College CD59 para inhibir la activación del inflamasoma

Also Published As

Publication number Publication date
CN118369333A (zh) 2024-07-19
KR20240107156A (ko) 2024-07-08
JOP20240112A1 (ar) 2024-05-16
WO2023089564A1 (en) 2023-05-25
JP2024540470A (ja) 2024-10-31
MX2024006087A (es) 2024-05-30
AU2022394125A1 (en) 2024-07-04
EP4433496A1 (en) 2024-09-25
US20250018063A1 (en) 2025-01-16
CA3237907A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
JP2024037864A5 (https=)
IL312903A (en) Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59
JP2021531288A5 (https=)
Al-Saikhan The gene therapy revolution in ophthalmology
RU2012154574A (ru) Способы и композиции для доставки в цнс арилсульфатазы а
RU2012154575A (ru) Способы и композиции для доставки к цнс идуронат-2-сульфатазы
WO2021021931A1 (en) Materials and methods for treating friedreich's ataxia
AU2010336475A1 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
US20190225660A1 (en) Method of treating and preventing ocular angiogenesis
CN110678193A (zh) 治疗和神经保护肽
EP4389894A2 (en) Riboswitch modulated gene therapy for retinal diseases
EP2909232B1 (en) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (amd)
CN113577083A (zh) 一种小分子化合物组合在制备预防和治疗视网膜损伤性疾病药物中的应用
JP2022548367A (ja) 眼科障害の処置または防止における使用のための薬剤
Chang Challenges of treatment methodologies and the future of gene therapy and stem cell therapy to treat retinitis pigmentosa
CN111905103A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
US20200390853A1 (en) Active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof
KR102518033B1 (ko) 수퍼옥시드 디스뮤타제 및 이의 당뇨망막병증 또는 포도막염의 예방 또는 치료용 용도
US20230381186A1 (en) Compounds and Methods for Treating or Preventing Anterior Segment Ocular Disorders and/or Retinal Degenerations
RU2277413C2 (ru) Способ лечения вторичной дистрофии роговицы
WO2009026614A1 (en) Hypoglycaemic tripeptide and methods of use thereof
CN101724653A (zh) 一种含利钠肽基因的药物及制备方法和应用
Derkach et al. Modern approaches to the retinitis pigmentosa treatment in the older age patients (literature review)
EP3397271B1 (en) Compositions and methods for treating retinopathy
WO2009042708A1 (en) Regeneration anti-inflammatory composition and method for treating a retinal dystrophy using same